VEGF inhibitors and complement inhibitors for macular degeneration and diabetic eye disease
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Massachusetts Policy 092 alerts
Get alerted when Policy 092 changes without checking for updates manually.
Monitor payer policy activity
Clinical coverage and prior authorization requirements for VEGF inhibitors and complement inhibitors used to treat macular degeneration, diabetic eye disease, and related retinal conditions for BCBSMA commercial members.
Updated Eylea HD with expanded FDA indications.
Removed Eylea and Pavlu from Cotivity program.
Clarified no prior authorization required for any bevacizumab with ophthalmic administration.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.